1. Home
  2. VERU vs INCR Comparison

VERU vs INCR Comparison

Compare VERU & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.42

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Logo Intercure Ltd.

INCR

Intercure Ltd.

HOLD

Current Price

$0.75

Market Cap

42.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERU
INCR
Founded
1971
1994
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
42.3M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VERU
INCR
Price
$2.42
$0.75
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
44.5K
16.6K
Earning Date
05-07-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,296,958.00
N/A
Revenue This Year
N/A
$69.54
Revenue Next Year
N/A
$41.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.36
$0.68
52 Week High
$4.59
$1.77

Technical Indicators

Market Signals
Indicator
VERU
INCR
Relative Strength Index (RSI) 50.07 45.84
Support Level $2.13 $0.72
Resistance Level $2.67 $0.79
Average True Range (ATR) 0.12 0.03
MACD 0.01 0.01
Stochastic Oscillator 51.16 57.14

Price Performance

Historical Comparison
VERU
INCR

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About INCR Intercure Ltd.

Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.

Share on Social Networks: